Ampliphi Biosciences (NYSEAMERICAN:APHB) Shares Up 3.7% - Time to Buy?

Key Points

• Ampliphi Biosciences shares increased by 3.7%, reaching a last trading price of $2.54, although the trading volume was significantly lower than average.
• The company's focus is on developing therapies for antibiotic-resistant infections using bacteriophage-based technology, with products like AB-SA01 and AB-PA01 for S. aureus and P. aeruginosa infections, respectively.
• Ampliphi has a fifty-day moving average of $2.12 and a two-hundred-day moving average of $1.86, suggesting a positive trend relative to its recent performance.

Ampliphi Biosciences Corp (NYSEAMERICAN:APHB - ) shares rose 3.7% during trading on Tuesday . The company traded as high as $2.54 and last traded at $2.54. Approximately 2,245 shares were traded during mid-day trading, a decline of 100% from the average daily volume of 842,200 shares. The stock had previously closed at $2.45.

Ampliphi Biosciences Stock Up 3.7%

The company has a fifty day moving average of $2.12 and a two-hundred day moving average of $1.86.

About Ampliphi Biosciences

AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus (S. aureus) infections; and AB-PA01 for the treatment of pseudomonas aeruginosa (P.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.